ライフサイエンスコーパス: filariasis

1 n in a chronic helminth infection (lymphatic filariasis).

2 iethylcarbamazine (IDA) regime for Lymphatic Filariasis.

3 erlying T cell immune tolerance in lymphatic filariasis.

4 fic T-cell response seen in patent lymphatic filariasis.

5 he vector-borne parasitic disease, lymphatic filariasis.

6 account for the T cell hyporesponsiveness in filariasis.

7 erlying the dysfunctional immune response in filariasis.

8 North Americans with no history of lymphatic filariasis.

9 ecology and pathogenesis of human lymphatic filariasis.

10 (H2(d)), the only fully permissive model of filariasis.

11 seases such as river blindness and lymphatic filariasis.

12 n of programs aimed at eliminating lymphatic filariasis.

13 symbionts into the blood after treatment for filariasis.

14 malayi, a causative agent of human lymphatic filariasis.

15 the heterogeneous distribution of lymphatic filariasis.

16 or nonantigenemic individuals with clinical filariasis.

17 ofile are well-established features of human filariasis.

18 gamma- and IL-4-producing cells in lymphatic filariasis.

19 infection and morbidity rates in bancroftian filariasis.

20 e of the causative agents of human lymphatic filariasis.

21 sociated with cytokine patterns in lymphatic filariasis.

22 elimination of onchocerciasis and lymphatic filariasis.

23 ited at 12 months and retested for lymphatic filariasis.

24 or the prevention and treatment of lymphatic filariasis.

25 e serum N-glycans are specific for lymphatic filariasis.

26 eading to an effective therapy for lymphatic filariasis.

27 ALB to annual IA in persons with bancroftian filariasis.

28 sis, as well as onchocerciasis and lymphatic filariasis.

29 drugs that cure onchocerciasis and lymphatic filariasis.

30 d parasitic nematodes resulting in lymphatic filariasis.

31 rugia malayi, a causative agent of lymphatic filariasis.

32 ntial to accelerate elimination of lymphatic filariasis.

33 diseases like river blindness and lymphatic filariasis.

34 i, one of the nematodes that cause lymphatic filariasis.

35 nia africana, which are vectors of lymphatic filariasis.

36 as well as of nematodes that cause lymphatic filariasis.

37 e Brugia malayi, an agent of human lymphatic filariasis.

38 mosquitoes that transmit West Nile fever and filariasis.

39 concept of protective immunity in lymphatic filariasis, 19 adult residents of a Wuchereria bancrofti

40 oncepts of disease progression (asymptomatic filariasis = 25%; clinical filariasis with active infect

41 with a low baseline prevalence of lymphatic filariasis (5%), the triple-drug regimen reduced the num

42 survey data of schistosomiasis and lymphatic filariasis across four countries.

43 ases including river blindness and lymphatic filariasis affect hundreds of millions of people annuall

44 m of rapid transmission-blocking activity of filariasis after depletion of Wolbachia and adds to the

45 carbamazine (DEC) is used to treat lymphatic filariasis and activates TRP-2, GON-2 & CED-11 TRP chann

46 asymptomatic microfilaremic or with clinical filariasis and active infection).

47 associated with disease in chronic lymphatic filariasis and could potentially have an important role

48 ore effective than DEC + ALB for Bancroftian filariasis and has the potential to accelerate eliminati

49 Lymphatic filariasis and intestinal helminth infections are import

50 Lymphatic filariasis and loiasis are major human diseases caused b

51 nets are being widely used in areas in which filariasis and malaria are coendemic.

52 d by filarial nematodes, including lymphatic filariasis and onchocerciasis (river blindness) has tran

53 Lymphatic filariasis and onchocerciasis are neglected tropical dis

54 Lymphatic filariasis and onchocerciasis are parasitic helminth dis

55 Lymphatic filariasis and onchocerciasis are parasitic helminth dis

56 Lymphatic filariasis and onchocerciasis cases responded well to co

57 Although lymphatic filariasis and onchocerciasis have been targeted for glo

58 ger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infe

59 Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial en

60 Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the

61 or parasitic worms responsible for lymphatic filariasis and onchocerciasis, devastating human illness

62 cycline treatment regimens against lymphatic filariasis and onchocerciasis.

63 in the global effort to eliminate lymphatic filariasis and possibly for the control of other mosquit

64 enya, where BCG is administered at birth and filariasis and schistosomiasis are endemic, were examine

65 administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in R

66 the antimorbidity effects of doxycycline in filariasis and support clinical evaluation of second-gen

67 ticle reviews available diagnostic tests for filariasis and their potential use as tools for differen

68 hieve their elimination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and their contr

69 worms such as Brugia, which causes lymphatic filariasis and Trichuris, one of the soil-transmitted he

70 to reduce microfilariae in blood (lymphatic filariasis) and skin (onchocerciasis).

71 seases, including West Nile virus, lymphatic filariasis, and avian malaria, posing a constant threat

72 of Kenya where schistosomiasis, bancroftian filariasis, and geohelminth infections are endemic.

73 tic agents against onchocerciasis, lymphatic filariasis, and heartworm.

74 h as guinea worm, schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that many of th

75 panosomiasis, Chagas disease, leishmaniasis, filariasis, and schistosomiasis.

76 s employed against onchocerciasis, lymphatic filariasis, and several other parasitic diseases in huma

77 lymphoedema, and elephantiasis in lymphatic filariasis, and skin disease and blindness in onchocerci

78 ases including West Nile virus and lymphatic filariasis, and transmit pathogens threatening livestock

79 an area highly endemic for schistosomiasis, filariasis, and tuberculosis in Kenya would either fail

80 within-host population dynamics of lymphatic filariasis, and use a simulated goodness-of-fit (GOF) me

81 d Th1 responses observed in patent lymphatic filariasis are associated with decreased expression of T

82 Global efforts to eliminate lymphatic filariasis are based on the annual mass administration o

83 is, cryptosporidiosis, strongyloidiasis, and filariasis) as well as travelers' diarrhea and vaccinati

84 earance or community prevalence of lymphatic filariasis at 12 months, and no improved efficacy follow

85 mpaigns against onchocerciasis and lymphatic filariasis being conducted in areas where Onchocerca vol

86 ponsible for malaria (Plasmodium), lymphatic filariasis (Brugia,Wuchereria bancrofti), giardiasis (Gi

87 ential for school-based control of lymphatic filariasis by investigating the efficacy and tolerabilit

88 potentially fatal complication of lymphatic filariasis, by mechanisms that are incompletely understo

89 th ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because

90 The number of filariasis cases decreased from 21.5/year on average in

91 Brugian filariasis (caused by the nematodes Brugia malayi and B.

92 te detection is essential for the success of filariasis control programs.

93 hylcarbamazine and albendazole for lymphatic filariasis control.

94 ity, validating it as a potential target for filariasis control.

95 ous diseases (Toxocara canis, strongyloides, filariasis, cysticercosis, fasciola, trichinella, echino

96 ver, few such programmes exist for lymphatic filariasis, despite evidence that single-dose treatment

97 We reviewed all cases of filariasis diagnosed at the Institute of Tropical Medici

98 s, whether with subclinical or with clinical filariasis, distinct and limited T cell populations are

99 idence that protective immunity to lymphatic filariasis does occur and that it is probably T cell-med

100 Conventional oral therapy of lymphatic filariasis drugs is only effective to kill microfilariae

101 rial antigens affects the natural history of filariasis during childhood.

102 Lymphatic filariasis (elephantiasis) is a global public health pro

103 immunocompromised mouse models suggest that filariasis elicits a complex host immune response involv

104 prevalence levels associated with lymphatic filariasis elimination pose a challenge for effective di

105 Improved diagnostic tests are needed for filariasis elimination programs (to identify areas of en

106 tential use as tools for different phases of filariasis elimination programs.

107 in A is an antibiotic to develop further for filariasis elimination without concern for cross-resista

108 es, including dengue, malaria, and lymphatic filariasis, exact a devastating toll on global health an

109 nvestigated in Malian villages coendemic for filariasis (Fil) and malaria.

110 Lymphatic filariasis, frequently caused from Wuchereria bancrofti

111 al to assist programs in achieving lymphatic filariasis goals.

112 The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain infection

113 ting Global Programme to Eliminate Lymphatic Filariasis (GPELF) is largely based on a strategy of mas

114 The Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to

115 The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of

116 The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of

117 The Global Program to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the princip

118 l Programme for the Elimination of Lymphatic Filariasis (GPELF), as interaction dynamics may change w

119 the Global Programme to Eliminate Lymphatic Filariasis (GPELF).

120 e elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of

121 verall, ccfDNA/ccfRNA detection in lymphatic filariasis holds promise for assessment of infection and

122 l to accelerate the elimination of lymphatic filariasis if high population coverage of mass drug admi

123 l to accelerate the elimination of lymphatic filariasis if high population coverage of mass drug admi

124 ity impact of IDA vs DA as MDA for lymphatic filariasis in 35 villages on 2 islands of Fiji.

125 eeded to accelerate elimination of lymphatic filariasis in Africa.

126 for control of onchocerciasis and lymphatic filariasis in Africa.

127 ration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and iver

128 en for accelerating elimination of lymphatic filariasis in different epidemiological settings.

129 We give case examples including filariasis in eastern Burma and vector-borne diseases (C

130 ns is the cause of the second most prevalent filariasis in Gabon, but so far reports on the presence

131 methodology using a case study of lymphatic filariasis in Ghana, demonstrating that a geostatistical

132 cellular parasites responsible for lymphatic filariasis in humans--and the APC with which they come i

133 rugia malayi, a causative agent of lymphatic filariasis in humans.

134 Information on human filariasis in international travelers is scarce.

135 y in the developing world, causing lymphatic filariasis in nearly 40 million people.

136 Onchocerciasis and lymphatic filariasis in particular are the cause of much disfigure

137 The burden and species distribution of filariasis in travelers evolved in the past decades.

138 nematode of humans responsible for lymphatic filariasis, in a longitudinal cohort of infected rhesus

139 is a severe asthmatic syndrome of lymphatic filariasis, in which an allergic response is induced to

140 Drugs to treat filariasis include diethylcarbamazine, ivermectin, and a

141 r knowledge of the host-seeking behaviour of filariasis infected mosquitoes is lacking.

142 to be qualitatively different from those of filariasis-infected subjects; whereas filarial antigens

143 To determine whether maternal filariasis influences the risk of infection by and immun

144 and the effectiveness of currently proposed filariasis intervention options.

145 Lymphatic filariasis is a disease characterized by immune dysregul

146 Bancroftian filariasis is a major public health problem in Papua New

147 ent global initiative to eliminate lymphatic filariasis is a major renewed commitment to reduce or el

148 Lymphatic filariasis is a tropical disease caused by the nematode

149 Lymphatic filariasis is a vector-borne neglected tropical disease

150 Patent lymphatic filariasis is characterized by a profound down-regulatio

151 Patent lymphatic filariasis is characterized by antigen-specific T-cell u

152 Patent lymphatic filariasis is characterized by profound Ag-specific T ce

153 Humans living in areas where filariasis is endemic vary greatly in their exposure to

154 On an island in which bancroftian filariasis is endemic, 29 microfilaremic and 16 "endemic

155 ss-sectional study in an area of Kenya where filariasis is endemic.

156 n living on a Pacific island where lymphatic filariasis is endemic.

157 ic T-cell unresponsiveness seen in lymphatic filariasis is mediated, in part, by diminished antigen-p

158 d from individuals from North America, where filariasis is not endemic, were also positive for anti-W

159 ma development in individuals with lymphatic filariasis is presently poorly understood.

160 ctra of clinical manifestations of lymphatic filariasis is still unknown.

161 Elimination of onchocerciasis and lymphatic filariasis is targeted for 2020.

162 Lymphatic filariasis is targeted for elimination as a public healt

163 Lymphatic filariasis is the major global cause of nonhereditary ly

164 One of the causative agents of lympahtic filariasis is the nematode parasite Brugia malayi that r

165 Chagas disease, filariasis, leishmaniasis, malaria and schistosomiasis a

166 Lymphatic filariasis (LF) afflicts over 60 million people worldwid

167 Lymphatic filariasis (LF) and onchocerciasis are priority neglecte

168 Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance

169 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020.

170 chieving the global elimination of lymphatic filariasis (LF) by 2020.

171 Malaria and lymphatic filariasis (LF) continue to cause a considerable public

172 y considered an important tool for lymphatic filariasis (LF) elimination but is not usually included

173 a recommended approach to support lymphatic filariasis (LF) elimination efforts.

174 DA) programs that aim to eliminate lymphatic filariasis (LF) in Africa.

175 are currently at risk of acquiring lymphatic filariasis (LF) in over 52 countries worldwide.

176 possible strategy for eliminating lymphatic filariasis (LF) in post-conflict countries such as the D

177 Lymphatic filariasis (LF) is a debilitating, poverty-promoting, ne

178 Lymphatic filariasis (LF) is a major cause of acute and chronic mo

179 The global elimination of lymphatic filariasis (LF) is a major focus of the World Health Org

180 Lymphatic filariasis (LF) is a neglected tropical disease targeted

181 Human lymphatic filariasis (LF) is primarily caused by the helminth para

182 The familial recurrence risk of lymphatic filariasis (LF) is unknown.

183 he global drive for elimination of lymphatic filariasis (LF), 15 countries have achieved validation o

184 ublic health importance, including lymphatic filariasis (LF), as well as many arboviral diseases.

185 tropical diseases (NTD), including lymphatic filariasis (LF), scaled up dramatically after the signin

186 ommunities tasked with eliminating lymphatic filariasis (LF), the underlying cause of elephantiasis a

187 lymphatic filariasis (LF).

188 d one of the etiological agents of Lymphatic filariasis (LF).

189 cornerstone for the elimination of lymphatic filariasis (LF).

190 in strategy for the elimination of lymphatic filariasis (LF).

191 These foci are coendemic with lymphatic filariasis (LF).

192 A) with albendazole (ALB) alone on lymphatic filariasis (LF).

193 Using rodent models of lymphatic filariasis (Litomosoides sigmodontis) and noncerebral ma

194 In a laboratory model of filariasis, Litomosoides sigmodontis infection of suscep

195 ls with clinical manifestations of lymphatic filariasis may be currently infected or not.

196 ce with Wuchereria bancrofti due to maternal filariasis may influence susceptibility to infection.

197 Lymphatic filariasis occurs in endemic pockets.

198 or the diagnostic evaluation of persons with filariasis of unclear etiology.

199 the data available for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helminthiasis, sc

200 amples from patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or other helm

201 amely gambiense sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transm

202 oadministration of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transm

203 mitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma, visceral leishmani

204 from filarial nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blocked worm

205 - to 10-year-old children of mothers without filariasis or schistosomiasis produced 10-fold more IFN-

206 ed helminthiases, schistosomiasis, lymphatic filariasis) or elimination of transmission (onchocercias

207 duals, antigenemic individuals with clinical filariasis, or nonantigenemic individuals with clinical

208 the nonantigenemic individuals with clinical filariasis (P = 0.02).

209 the nonantigenemic individuals with clinical filariasis (P = 0.04).

210 no prior mass drug administration (MDA) for filariasis (Papua New Guinea and Indonesia), and three s

211 or less, were overrepresented in any single filariasis patient.

212 est this hypothesis in bancroftian lymphatic filariasis, pedigree data were collected twice during an

213 Bancroftian filariasis remains endemic in Fiji despite >10 years of

214 Elimination of filariasis requires a macrofilaricide treatment that can

215 ugia malayi, a human parasite widely used in filariasis research.

216 ever and yellow fever viruses, and lymphatic filariasis, respectively.

217 rugia malayi, a causative agent of lymphatic filariasis, resulting in the identification of more than

218 Focussing on lymphatic filariasis, schistosomiasis and soil-transmitted helmint

219 Parasitic infections such as filariasis, schistosomiasis, and amoebiasis can be assoc

220 s, could be administered as short courses to filariasis target populations with potential to reduce a

221 ewed and given a physical examination before Filariasis Test Strip and Wb123 testing.

222 Wuchereria bancrofti antigen (determined by Filariasis Test Strip) and specific IgG4 (determined by

223 the nonantigenemic individuals with clinical filariasis than in the asymptomatic microfilaremic indiv

224 and Th2 immune responses occurs in lymphatic filariasis that is governed at the transcriptional level

225 h the putatively immune state in bancroftian filariasis (that is, both microfilaria and antigen free)

226 site products has been investigated in human filariasis to understand immune hyporesponsiveness.

227 elimination and control of 5 NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis, a

228 iasis, soil-transmitted helminths, lymphatic filariasis, trachoma, onchocerciasis, visceral leishmani

229 Mathematical models of filariasis transmission can serve as an effective tool f

230 nitor populations for possible resurgence of filariasis transmission following suspension of MDA.

231 study of diseases as diverse as lymphedema, filariasis, transplant rejection, obesity, and tumor met

232 Thus, in Mf(-) mice, filariasis upset a delicate immunological balance in mal

233 Culex pipiens mosquito group (including the filariasis vector C. quinquefasciatus) a very unusual de

234 ry signal for sex determination in the human filariasis vector mosquito, Ar. subalbatus.

235 quinquefasciatus are important arboviral and filariasis vectors, however despite this important epide

236 e rounds of community-wide MDA for lymphatic filariasis, was divided into 40 clusters (population >=1

237 ite of disease activity in human bancroftian filariasis, we have compared the repertoire of TCR Vbeta

238 ls and antigenemic individuals with clinical filariasis were grouped together to constitute all activ

239 toes introduce the pathogens responsible for filariasis, West Nile virus, St.

240 Human lymphatic filariasis, which afflicts an estimated 120 million peop

241 , tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burden

242 ion (asymptomatic filariasis = 25%; clinical filariasis with active infection = 60%; clinical filaria

243 ymptomatic microfilaremic or having clinical filariasis with active infection or without current acti

244 rasites has provided a new approach to treat filariasis with antibiotics.

245 e and well-tolerated treatment for lymphatic filariasis with significant activity against adult worms

246 malayi, a causative agent of human lymphatic filariasis, with PBMC of normal individuals.

247 riasis with active infection = 60%; clinical filariasis without active infection = 71%).

248 ma were seen only in the group with clinical filariasis without active infection.

249 ne treatment on the major cause of lymphatic filariasis, Wuchereria bancrofti.